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Summary:  We describe aetiology and long-term outcomes of sepsis in Malawi, to inform 
urgently-needed locally-adapted sepsis protocols. Disseminated tuberculosis dominates and 
receipt of antituberculous chemotherapy is associated with survival.  Significant post-




























Sepsis protocols in sub-Saharan Africa (sSA) are typically extrapolated from high-income 
settings, yet sepsis in sSA is likely caused by distinct pathogens and may require novel 
treatment strategies. Data to guide such strategies are lacking. We aimed to define causes 
and modifiable factors associated with sepsis outcome in Blantyre, Malawi to inform design 
of treatment strategies tailored to sSA. 
 
Methods 
We recruited 225 adults meeting a sepsis case-definition defined by fever and organ 
dysfunction, in an observational cohort study at a single tertiary centre. Aetiology was 
defined using culture, antigen detection, serology and PCR. Effect of treatments on 28-day 
outcomes were assessed by Bayesian logistic regression. 
 
Results 
143/213 (67%) of participants were HIV-infected. We identified a diagnosis in 145/225 (64%) 
participants: most commonly tuberculosis (34%) followed by invasive bacterial (17%) and 
arboviral infections (13%) and malaria (9%) Tuberculosis was associated with HIV infection 
whereas malaria and arboviruses with the absence of HIV infection. Antituberculous 
chemotherapy was associated with survival (aOR 28-day death 0.17 [95% CrI 0.05-0.49] for 
receipt of antituberculous therapy).  Of those with confirmed aetiology, 83% received the 





















Sepsis in Blantyre, Malawi, is caused by a range of pathogens; the majority are not 
susceptible to the broad-spectrum antibacterials that most patients receive. HIV status is a 
key determinant of aetiology. Novel antimicrobial strategies for sepsis tailored to sSA – 
including consideration of empiric antitubercular therapy in the HIV-infected - should be 
developed and trialed. 
 























Sepsis, a life-threatening organ dysfunction triggered by a dysregulated host response to 
infection[1], is estimated to cause 11 million deaths worldwide per year, with a 
disproportionate burden on Low and Middle Income Countries (LMIC) including sub-Saharan 
Africa (sSA)[2]. Progress in improving sepsis outcomes in high-income settings has been 
made through early recognition and timely delivery of basic care including rapid 
administration of appropriate antimicrobial therapy and fluid resuscitation[3]. In sSA, 
however, mortality remains high[4].  
 
Many aspects of optimal sepsis management are, in principle, deliverable in resource-limited 
hospitals, but applying sepsis protocols derived from high-resource settings to hospitals in 
sSA has resulted in unexpected results, the most well-known being the harmful effect of 
liberal intravenous fluid therapy[5,6]. To develop LMIC-targeted sepsis protocols, data from 
LMIC are urgently needed. This was highlighted in the recent WHO global report on the 
epidemiology and burden of sepsis[7] in which sepsis aetiology and long-term sequelae 
were identified as particular gaps.  
 
Standard antimicrobial treatment for sepsis in both high- and low-resource settings typically 
consists of broad spectrum antibacterial therapy, but limited available data from sepsis[4,8] 
and fever aetiology[9] studies in sSA suggest that mycobacterial, viral, bacterial zoonotic or 
parasitic causes of illness are common and not covered by standard antibacterial 
therapy[10]. Data on sepsis aetiology beyond bloodstream infection in sSA are lacking[4], 
but aligning the causes of infection with their effective treatments is central to not only 
preventing death and disability, but also reducing unnecessary antimicrobial use, a key 




















To address these data gaps, we here provide a description of sepsis aetiology in Blantyre, 
Malawi, describe long-term sepsis outcomes and identify elements of current sepsis 




Study setting and design 
 
We undertook an observational cohort study recruiting at Queen Elizabeth Central Hospital 
(QECH), Blantyre, Malawi, a 1300-bed government teaching hospital providing free 
healthcare to the city (2018 population 800,064[11]). Malawi is a low-income country in 
South-East Africa, with an estimated adult HIV prevalence of 9%[12], and a tuberculosis 
incidence of 133/100,000 person-years[13]. Blantyre has a subtropical climate with a rainy 
season from November to April. Malaria is endemic, peaking in the rainy season[14]. In this 
study, adults (≥16 years) with sepsis were recruited from the emergency department 0700-
1700 Monday-Friday. As study design predated Sepsis-3 guidelines, inclusion criteria were 
evidence of infection (fever [axillary temperature > 37.5°C] or history of fever within 
preceding 72 hours) plus ≥ one clinical marker of immediate organ dysfunction or locally 
predictive of poor outcome [15,16]: oxygen saturation < 90%; respiratory rate > 30 
breaths/minute; systolic blood pressure < 90 mmHg; or Glasgow coma scale < 15. These 
selection criteria were chosen because they are applicable in our setting and regionally 
generalisable. Exclusion criteria were: participants lacking capacity to consent with no 
guardian available for proxy consent; participants speaking neither Chichewa nor English; 



















the participant or, if they lacked capacity, their accompanying guardian. All care and 
treatment decisions for enrolled participants remained with the usual clinical team. Study 
team members followed participants hourly for the first six hours of hospital admission, then 
daily whilst an inpatient then in person at days 28, 90 and 180.  
 
Sampling and laboratory methods 
 
Patients provided blood and urine at baseline and blood at day 28. Full details of 
tests/assays are in Supplementary Methods. In brief, blood was tested for HIV-1/2 
antibodies, P. falciparum HRP-2 antigen, standard biochemical and hematologic analyses, 
CD4 cell count quantification, automated aerobic culture and mycobacterial culture (HIV-
infected/HIV-unknown participants only). Sputum testing for tuberculosis using Xpert 
MTB/RIF was carried out when there was a suspicion of pulmonary tuberculosis and CSF 
microscopy, culture and lateral flow cryptococcal antigen testing when there was a suspicion 
of meningitis from the clinical team. 
 
The following additional diagnostic tests were necessarily batched: urinary 
lipoarabinomannan (LAM, HIV-infected/HIV-unknown participants only) and testing of acute 
and convalescent sera for antibodies to Chikungunya, Dengue and Leptospira, and 
convalescent sera for spotted fever group and epidemic typhus group Rickettsioses. In 
addition, a subset of serum samples underwent PCR for 46 bacterial and viral pathogens 
(Supplementary methods). Case definitions are explained in Table 1. The study was 
designed and carried out before the WHO strong recommendation for LAM testing in 























All analyses were carried out in R v4.0.2 (R Foundation for Statistical Computing, Vienna, 
Austria) and all models fitted with Stan v2.21.0 via the R brms v2.13.5 package[18,19].  
 
The analysis aimed to identify modifiable treatment-related associations of sepsis mortality 
(full details in Supplementary Methods). In brief, we hypothesised a causal structure 
(Supplementary Figure E1) to identify which variables to control for to estimate a causal 
effect of treatments on outcome. We used principal component analysis (PCA) to reduce the 
dimensionality of host-severity variables (Supplementary Table E1 and Figure E8), and used 
these along with untransformed infection and treatment variables as covariates in Bayesian 
logistic regression models with death by 28-days as the outcome. Missing data (which were 
infrequent, Supplementary Figure E10) were imputed with chained equations. Model outputs 
are presented as odds ratios (OR) with a point estimate (posterior median) with 95% credible 
intervals (CrI), or marginal effect of the predictor on the probability of outcome with 95% 
credible intervals for nonlinear models. 
 
Finally, Kaplan-Meier plots were used to estimate the survival function over the study period, 
stratified by HIV status with hazard ratios (posterior median and 95% CrI) for HIV infection vs 





















The study was approved by the University of Malawi College of Medicine (P.11/16/2063) and 
Liverpool School of Tropical Medicine (16-062) research ethics committees and is reported 
following the STROBE (Strengthening the Reporting of Observational Studies in 
Epidemiology) guidelines[20]. Data and code to replicate this analysis are available as the 






Between 19th February 2017 and 2nd October 2018, 225 participants were recruited (Table 2, 
Supplementary Figure E2). 143/213 (67%) of participants were HIV-infected. Antiretroviral 
therapy (ART) coverage was high: of the HIV infected, 117/143 (82%) were on ART, 94% 
(110/117), the Malawian first-line regimen of efavirenz, lamivudine and tenofovir disoproxil, 
for a median of 29 (4-73) months. Despite this, CD4 counts were low for those on ART 
(median 98 [IQR 31-236]) and immunologic failure was common with 52/84 (62%) of 
participants on ART for longer than six months having a CD4 count below 200 cells /mL. 
HIV-infected participants were older than HIV uninfected participants, more likely to be 
female, been unwell for longer and with more severe disease at baseline as evidenced by a 
higher heart rate, lower blood pressure and less likely to be able to stand unaided 






















The majority of participants (207/225 [92%]) were administered broad-spectrum antibacterial 
agents (median [interquartile range IQR] 5.3 (3.7-10.8) hours from initial ED attendance), 
usually ceftriaxone (181/207 [87%], Supplementary Table E3), but also antituberculous 
(63/225 [28%]), antifungal (26/225 [12%]) or antimalarial (12/225 [5%]) therapy. Median 
(IQR) duration of ceftriaxone was 5 (2-7) days. Only patients with a positive malaria rapid 
test received antimalarial therapy. 192/225 (85%) of participants received intravenous fluid: a 
median of 1.5L of fluid (IQR 1.0-2.0L) in the six hours following enrollment. None of the 
participants received inotropes, were intubated, or admitted to the intensive care unit. Only 




A diagnosis was made 174 times in 144/225 (64%) participants (Table 3), most commonly 
tuberculosis, in 34% (95% confidence interval, CI 28-41%). Acute rickettsioses and 
leptospirosis (2% [95% CI 1-5%] and 1% [0.1-3.2%] of participants) were uncommon. 
Evidence of past exposure to spotted fever group rickettsioses, and Chikungunya however, 
was very common, with IgG detected in 61/147 (42% [95% CI 33-50%]) and 51/146 (35% 
[95% CI 27-43%]) convalescent serum samples, respectively (Supplementary Table E4, 
Supplementary Figure E3). 
 
The commonest invasive bacterial pathogens identified on aerobic culture or PCR (43 
pathogens in 38 participants, Supplementary Figures E4, E5) were Streptococcus spp. 
(13/38 participants, 6 of which were pneumococcus), non-Salmonella Enterobacterales 
(12/38), and Salmonella spp. (11/38). Results of antimicrobial sensitivity testing are given in 



















those who reported taking CPT were diagnosed with an invasive bacterial infection, 
compared to 7/43 (16%) of those not reporting taking CPT. All invasive fungal disease was 
caused by Cryptococcus, either C. neoformans cultured from both blood and CSF (n=3), 
CSF alone (n=1) or detectible cryptococcal antigen in CSF (n=1). Of the 76 diagnoses of 
tuberculosis, two were pulmonary (positive Xpert MTB/RIF only), and the rest disseminated 
and all but one of the participants with tuberculosis were HIV-infected (Table 3). This patient 
group (disseminated tuberculosis) was clinically similar to the rest of the cohort 
(Supplementary Table E5). Of the 63 participants who received antituberculous therapy, 
37/63 (59%) had a confirmed diagnosis of tuberculosis. Only 37/76 (49%) participants with 
tuberculosis received antituberculosis therapy. 
 
HIV infection predicted sepsis aetiology (Table 4, Supplementary Table E6): malaria and 
arboviruses were more common in the HIV uninfected (malaria 17% vs 4% [difference 13% 
95% CI 4-22]), arbovirus 27% vs 6% [difference 22% 95% CI 11-33] for HIV infected vs 
uninfected)  whereas invasive fungal disease only occurred in in HIV infected participants, 
and TB was more common in HIV infected participants (1% vs 50% [difference 48% 95% CI 
40-57%] HIV uninfected vs infected). Invasive bacterial infections occurred at similar 
proportions in HIV-infected and uninfected participants (20% vs 15% [difference 5% 95% CI 
-5-17]). Whilst there were some co-infections, most participants with a diagnosis had a single 
aetiologic agent, (113/145, 78%: Figure 1, Supplementary Figure E6). Of the patients with a 
microbiologically confirmed diagnosis, only 35/145 (24%) were predicted to be susceptible to 
ceftriaxone but 120/145 (83%) received it (Figure 1).  
 




















Median (IQR) follow up time was 182 (62-202) days, a total of 92 person-years. Case fatality 
ratio (CFR) was 39/222 (18% [95% CI 13-23]) at 28-days, and continued to increase 
thereafter to 51/215 (24% [95% CI 18-30%]) at 90-days and 60/194 (31% [95% CI 25-38%]) 
at 180-days; in-hospital CFR was 14% (95% CI 10-19%) and median (IQR) length of 
hospitalisation 5 (2-10) days. Early mortality was similar between HIV infected and 
noninfected participants, but diverged post-discharge (hazard ratio [HR] for death 2.0 [95% 
CrI 1.1-4.0] HIV infected vs uninfected, Figure 2). Mortality was similar across diagnoses 
though confidence intervals were wide (Table 5, Supplementary Figure E7). In an 
unadjusted analysis (Table 5), well recognized host and sepsis severity variables and 
inability to stand were associated with death. Receipt of antimalarials and antituberculous 
chemotherapy were associated with survival in univariable analysis. 
 
We used Bayesian logistic regression with PCA-transformed host-severity variables 
(Supplementary Table E1) to estimate the effect of sepsis treatments received by study 
participants.  Approximate leave-one-out cross validation showed that, comparing models 
with one to five PCA coordinates as predictors of death, three coordinates had the best out 
of sample predictive value (quantified by ELPD, Supplementary Table E7). This model 
(using PC1, 2 and 3) was used as the base model to assess the effect of sepsis treatments 
on mortality. Together PC1-3 explained 36% of the variance of the 18 included variables. 
PC1 defined an axis of HIV, immunosuppression and shock, PC2 included severe sepsis 
organ dysfunction (low oxygen saturation, low Glasgow coma score [GCS], high lactate and 
high creatinine), male sex and inability to stand and PC3 with thrombocytopenia, (Figure 3A, 
Supplementary Figure E9). All three transformed variables PC1-3 were associated with 




















Modelling the effect of different antimicrobial therapies found a convincing association only 
between antituberculous therapy and survival (adjusted odds ratio [aOR] of death by 28 days 
0.17 [95% CrI 0.05-0.49] for receipt of antituberculous therapy), (Figure 3C, Supplementary 
Table E8). In linear models, the effect of an hour of antimicrobial delay on 28 day mortality 
was estimated to be aOR 1.02 (95% CrI 0.99-1.04) and the effect of a litre of IV fluid to be 
aOR 0.52 (95% CrI 0.29-0.91, Supplementary Table E7). Relaxing the linearity assumption 
and allowing these relationships to be nonlinear time found no convincing relationship 
between time to antimicrobial therapy and death (Figure 3D), but was suggestive of a lower 




We demonstrate that adults presenting with sepsis in Blantyre, Malawi, are young compared 
to high-income settings, predominantly HIV-infected, and that their illness is caused by a 
heterogeneous group of pathogens, the majority of which are not susceptible to ceftriaxone. 
HIV status is the key determinant of sepsis aetiology. Long term outcomes are poor, driven 
by late mortality in HIV-infection. These data suggest several strategies that could improve 
sepsis outcomes in sSA. 
 
First, optimised antimicrobial strategies for sepsis in sSA are needed; ceftriaxone would be 
expected to be effective in only 24% of participants with a diagnosis, yet 83% received this 
drug (median 5 days). Ceftriaxone is a convenient, available drug in sSA, but widespread 
use in Malawi[21] and regionally has been associated increase in antimicrobial 
resistance[22,23]. Current diagnostic delays in establishing aetiology necessitate immediate 



















establish alternate diagnoses – perhaps with rapid diagnostic tests – rapid de-escalation of 
therapy and reduction of reliance on broad spectrum antibacterials could be possible.    
 
HIV status was the key determinant of sepsis aetiology, and represents a pragmatic starting 
point for management strategies. In particular, consideration of the need for antituberculous 
chemotherapy is indicated for HIV-infected people presenting with sepsis in high 
tuberculosis-burden settings. Tuberculosis was the most common diagnosis in this study, in 
34% of participants, and receipt of TB therapy was associated with improved survival (aOR 
of death 0.17 [95% CrI 0.05-0.49]). A strategy of universal testing using lateral flow LAM 
testing of HIV-infected inpatients was shown to improve survival in the STAMP trial[24] and 
the WHO recommends testing in all seriously ill HIV-infected inpatients[17]. Even with 
expected improved sensitivity of the FujiLAM assay[25], however, LAM testing is likely to 
miss cases of disseminated tuberculosis. Furthermore it can be challenging to get urine 
samples from critically ill patients in low resource units, yet in the critically ill it may be that 
delaying antituberculous therapy is associated with poorer outcomes[8]. Whilst empiric 
tuberculosis treatment has previously been assessed and is yet to demonstrate improved 
outcomes[26–28], none of these studies recruited inpatients with critical illness or sepsis. 
Our data suggests there is a case for such interventional trials for critically unwell HIV-
infected people, perhaps based on presumptive TB therapy with step down based on 
subsequent diagnostic testing. 
 
In contrast, in HIV-uninfected people, malaria and arboviral infections are important causes 
of sepsis, and more common than proven invasive bacterial infection. Indeed the striking 
prevalence of Chikungunya IgG seropositivity in study participants is comparable to well 
described outbreak[29] and suggests widespread community transmission, in keeping with 



















diagnostic tests for malaria has revolutionized the management of febrile illness in sSA; 
these data suggest that there may be a role for rapid arboviral tests as well.  
 
Secondly, post-discharge deaths must be addressed. We demonstrate significant long term 
mortality following sepsis, driven by late deaths in HIV-infected participants, perhaps due to 
ART failure and opportunistic infection. To our knowledge these are the first estimates of 
case fatality ratios for sepsis in sSA beyond 30 days. ART coverage in this cohort was high 
compared to historical cohorts[16,30] and reflects the success of the Malawian ART 
programme, thus a sepsis presentation is likely to be a manifestation of ART failure[31], but 
rates of switching to second-line therapy during the study period were very low. This may 
reflect programmatic challenges of documenting serial viral loads before switching, per WHO 
guidance[32]. Structural interventions which optimize the identification of ART failure in acute 
illness, and rapidly switch to second line therapy should be investigated. 
 
There are limitations to our study, especially around our ability to deliver comprehensive or 
real time diagnoses. It was only possible to carry out urinary LAM testing at the end of the 
study [17]. Serologic testing was largely carried out on convalescent sera and so we could 
not relate serologic diagnoses to survival. Testing IgG on paired sera would likely most 
accurately classify diagnoses, but was not possible because of resource limitations; 
serologic diagnoses of arboviruses and leptospirosis were based on IgM, which may be 
nonspecific. Rickettsial IgM particularly has poor specificity so an IgG based case definition 
was used, which may misclassify acute cases. Funding did not permit identification of some 
causes of febrile illness e.g. Coxiella serology for Q-fever or Pneumocystis jiroveci. We could 
not establish late causes of mortality, or provide HIV viral load testing. Malaria diagnosis 
used HRP-2 antigenaemia rather than smear for diagnosis, which could reflect recent but not 



















may have poor specificity[33]. Though we have used a principled modelling approach with 
an explicit hypothesized causal structure to identify associations of mortality, it is likely that 
residual confounding remains. The dataset is too small to model all treatments and 
diagnoses simultaneously, or to explore interaction effects (e.g. explore whether treatments 
are beneficial only in groups with confirmed disease). Though Blantyre is likely to be 
reasonably representative of an urbanising population in sSA, the study was carried out at a 
single centre. 
 
In conclusion, sepsis in Blantyre, Malawi is caused by a diverse group of pathogens 
including M. tuberculosis, arboviruses, and malaria, yet management relies on prolonged 
courses of broad spectrum antibacterial agents, which would not treat these pathogens. HIV 
status is a key determinant of outcome and can assist clinicians in targeting antimicrobial 
therapy. Long term outcomes are poor and driven by late deaths in HIV-infected people. 
Understanding the reasons for these late deaths is of prime importance. Optimizing and 
operationalizing treatment solutions in sSA will require both randomized controlled trials and 
pragmatic implementation science approaches, but the high mortality in these patient 
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TABLES 
Table 1: Case definitions used in the study.  
 
Diagnosis Case definition 
Invasive bacterial infection EITHER 
BLOODSTREAM INFECTION defined 
by culture of pathogenic bacteria from 
aerobic blood culture (with coagulase-
negative Staphylococci, Bacillus spp., 
diphtheroids and alpha-haemolytic 
Streptococci other than S. pneumoniae 
considered as contaminants) OR 
Detection of pathogenic bacterial DNA in 
blood by multiplex PCR 
OR 
MENINGITIS defined by culture of 



















definition of contaminants).   
Invasive fungal infection EITHER 
BLOODSTREAM INFECTION: Culture 
of fungus from blood or  
OR 
MENINGITIS: Culture of fungus from 
CSF OR Detectible cryptococcal antigen 
by lateral-flow assay in CSF 
Tuberculosis* EITHER 
M. tuberculosis cultured from blood 
OR 
M. tuberculosis detected in sputum with 
Xpert MTB/RIF 
OR 
Detectible urinary lipoarabinomannan in 
urine by Alere lateral flow assay 
Possible spotted fever group 
Rickettsiosis 
IgG convalescent serology titre ≥ 1:512 
Possible epidemic Typhus group 
Rickettsiosis 
Chikungunya Detectible IgM in either acute or 
convalescent serology or detectible 
pathogen DNA/RNA by PCR array 
Dengue 
Leptospirosis 
All other diagnoses Detectible pathogen DNA/RNA by PCR 
array (see supplementary methods for 
full list) 
 
*Pulmonary Tuberculosis = positive Xpert MTB/RIF, with no or negative urinary LAM and/or 
mycobacterial blood culture) All other identified tuberculosis = disseminated (positive urinary 

























































































Age (years), median (IQR) 36 (28-44) 
Male sex n/N (%) 114/225 (51%) 
HIV/TB status 
HIV infected*, n/N (%) 143/213 (67%) 
CD4 lymphocyte count (106/L), median (IQR) 156 (51-298) 
Receiving antiretroviral therapy, n/N (%) 117/143 (82%) 
Time on antiretroviral therapy (months), median (IQR) 29 (4-73) 
Receiving co-trimoxazole preventative therapy, n/N (%) 98/141 (70%) 
History of receiving TB treatment n/N (%) 37/225 (16%) 
Of those, currently receiving TB treatment n/N (%) 10/37 (27%) 
Physiology 
Temperature (°C), median (IQR) 38.5 (37.9-39.0) 
Heart rate (beats/min), median (IQR) 121 (102-132) 
Respiratory rate (breaths/min), median (IQR) 34 (32-38) 
Systolic blood pressure (mmHg), median (IQR) 99 (85-119) 
Diastolic blood pressure (mmHg), median (IQR) 66 (57-76) 
Oxygen saturation (%), median (IQR) 96 (94-98) 
Glasgow coma score < 15 n/N (%) 21/225 (9%) 
Unable to stand unaided n/N (%) 63/225 (28%) 
Length of time unwell for (days), median (IQR) 7 (3-14) 
Laboratory parameters 
Haemoglobin (g/dL), median (IQR) 10.8 (8.2-13.2) 
Platelets (109/l), median (IQR) 218 (146-297) 
White cell count (109/l), median (IQR) 6 (4-11) 
Sodium (mmol/L), median (IQR) 134 (130-137) 



















Bicarbonate (mmol/L), median (IQR) 19 (17-22) 
Creatinine (mmol/L), median (IQR) 76 (59-103) 
Lactate (mmol/L), median (IQR) 3.4 (2.3-5.2) 
 














Table 3: Diagnoses in study participants and proportion of participants with positive results. 
 
 
Proportion of participants with 
positive result 
Cohort prevalence 
Diagnosis n/N % 95% CI n/N % 95% CI 




24/224 11% (7-15%) 




17/122 14% (8-21%)    
Meningitis 0/44 0% (0-8%) 




















Proportion of participants with 
positive result 
Cohort prevalence 








2/147 1% (0-5%)    
Epidemic 
typhus group 
0/147 0% (0-3%)    
Any 
Rickettsiosis 
2/147 1% (0-5%) 2/225 1% (0-3%) 
Other 
Leptospirosis 2/179 1% (0-4%) 2/225 1% (0-3%) 
Borreliosis 1/122 1% (0-4%) 1/225 0% (0-3%) 
Mycobacterial infection 




3/224 1% (0-4%)    




5/224 2% (1-5%) 5/225 2% (1-5%) 
Viral Infection 
Arboviral infection 
Chikungunya 17/176 10% (6-15%) 
   
Dengue 14/180 8% (4-13%) 
   
Any arbovirus 
infection 





















Proportion of participants with 
positive result 
Cohort prevalence 
Diagnosis n/N % 95% CI n/N % 95% CI 
Rift Valley 
fever 




21/219 10% (6-14%) 21/225 9% (6-14%) 
NB: The denominator in the proportion of participants with positive results is the number of 





















































































Table 4: Proportion of participants with diagnosis stratified by HIV status.  
 
Diagnosis HIV+ HIV- Difference 
Arboviral infection 8/143 (6%) 19/70 (27%) 22% (95% CI 11 to 33) 
Invasive bacterial infection 21/143 (15%) 14/70 (20%) 5% (95% CI -5 to 17) 
Invasive fungal infection 5/143 (3%) 0/70 (0%) -3% (95% CI -7 to -1) 
Malaria 6/143 (4%) 12/70 (17%) 13% (95% CI 4 to 22) 
Tuberculosis 71/143 (50%) 1/70 (1%) -48% (95% CI -57 to -
40) 
 
Difference is proportion in HIV-uninfected minus proportion in HIV-infected with bias-

















































Table 5: Univariable associations with death by 28 days.  
 
Variable Died Survived Difference 
       Number of participants 39 183 - 
Host Variables 
Age (years) 36.4 (31.5-46.0) 35.9 (27.4-42.9) -0.5 (-8.1 to 3.2) 
Male sex 19 (49%) 93 (51%) 2% (-16 to 19%) 
HIV Infected* 27 (75%) 116 (67%) -6% (-21 to 11%) 
CD4 count 106 /L 41 (17-225) 188 (69-302) 147 (46 to 186) 
Haemoglobin (x109} g/dL) 9.1 (6.0-10.4) 11.0 (8.6-13.4) 1.9 (0.8 to 3.9) 
Severity Variables 
Temperature (C) 38.1 (37.7-38.8) 38.5 (38.0-39.0) 0.4 (0.0 to 0.7) 
Heart rate (beats/min) 123 (105-139) 120 (102-131) -3 (-13 to 6) 
Systolic BP (mmHg) 89 (76-121) 99 (87-119) 10 (-1 to 16) 
Diastolic BP (mmHg) 60 (52-81) 67 (57-76) 7 (1 to 14) 
Respiratory rate 
(breaths/min) 
34 (32-37) 34 (32-38) 0 (-2 to 2) 



















Variable Died Survived Difference 
GCS 15 (15-15) 15 (15-15) 0 (0 to 0) 
Unable to stand 27 (69%) 36 (20%) 
-50% (-65 to -
33%) 
Lactate (mmol/L) 4.9 (3.0-10.6) 3.2 (2.1-4.5) -1.7 (-6.2 to -0.1) 
White cell count (x109) 5.9 (3.5-11.0) 6.9 (4.6-11.5) 1.0 (-1.4 to 2.8) 
Platelet count (x109 /L) 182 (87-301) 223 (148-297) 42 (-31 to 73) 
Sodium (mmol /L) 131 (127-138) 134 (130-137) 3 (-1 to 6) 
Bicarbonate (mmol /L) 17 (14-21) 20 (17-22) 3 (0 to 5) 
Urea (mmol /L) 7.8 (4.5-14.3) 4.5 (3.2-7.0) -3.3 (-8.7 to -1.3) 
Creatinine (mmol /L) 90 (60-185) 73 (59-96) -17 (-47 to 7) 
Diagnosis 
Invasive bacterial infection 5 (13%) 32 (17%) 5% (-10 to 15%) 
TB 15 (38%) 61 (33%) -5% (-23 to 10%) 
Malaria 0 (0%) 21 (11%) 11% (7 to 16%) 
Invasive fungal infection 3 (8%) 2 (1%) -7% (-20 to -1%) 
Chikungunya 2 (5%) 15 (8%) 3% (-9 to 9%) 
Dengue 2 (5%) 12 (6%) 1% (-10 to 7%) 
No diagnosis 18 (46%) 64 (35%) -11% (-29 to 6%) 
Treatment Received 
Antibacterials 37 (95%) 167 (91%) -4% (-10 to 7%) 
Time to Antibacterials (hr) 4.7 (3.8-8.8) 5.3 (3.6-10.8) 0.6 (-1.1 to 1.7) 
Antifungals 7 (18%) 19 (10%) -8% (-23 to 3%) 
Antimalarials 0 (0%) 12 (7%) 7% (3 to 10%) 
Antimycobacterials 6 (15%) 57 (31%) 16% (0 to 27%) 
IV fluid over 6hr (L) 1.4 (1.0-2.0) 1.3 (0.6-2.0) -0.1 (-0.7 to 0.2) 
 
* 12 participants had unknown HIV status and are excluded from the denominator to 



















median (IQR) and categorical variables as proportions. Difference column shows difference 
in medians or difference in proportions with bias-corrected bootstrapped 95% confidence 





Figure 1: UpSet plot of diagnoses. Black circles in the lower half of the plot show 
diagnoses: either a single diagnosis (single circle) or two or more diagnoses (black circles 
linked by lines), with the large bar chart (top right) showing the number of participants with 
the indicated diagnosis or diagnoses. Only participants who had a diagnosis are included in 
this plot, and the five most frequent diagnoses shown, demonstrating that most participants 
had only one diagnosis. Red colour of bar indicates receipt of antibacterial therapy, showing 
that almost all participants received antibacterial therapy despite no demonstrated invasive 
bacterial infection in many cases. 
 
Figure 2: Kaplan-Meier estimate of survival function following sepsis admission, 
stratified by HIV status.  
 
Figure 3: Determinants of sepsis mortality. A: Host-severity principal components 1 and 
2 showing that PC1 defines an axis of HIV, immunosuppression (low CD4 count and 
anaemia) and shock (tachycardia, low blood pressure and bicarbonate) whereas PC2 is 
associated with sepsis-related organ dysfunction, age, and male sex. B: Participants 
projected onto PC1 and 2 showing that participants who die (red circles) tend to have 
immunosuppression and shock (upper right), other sepsis related organ dysfunction (lower 
left), or both (lower right). C-E: Outputs of models predicting death by 28 days. Adjusted 



















predicted mortality as a function of time to antibacterial therapy (D) or volume of intravenous 
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